Inhibition of PTP1B by farnesylated 2-arylbenzofurans isolated from Morus alba root bark: unraveling the mechanism of inhibition based on in vitro and in silico studies.

Abstract

Among the 2-arylbenzofuran derivatives isolated from Morus alba, the farnesylated 2-arylbenzofuran is a rarer constituent. The derivative has been reported to exert anti-obesity effect; however, its inhibitory effect on protein tyrosine phosphatase 1B (PTP1B) has not been investigated. In the previous study, the presence of the farnesyl group in the structure of 2-arylbenzofurans was found to have positive influences on their pancreatic lipase inhibitory activity. In the present study, we have confirmed the authenticity of the notation based on the PTP1B inhibitory activity of farnesylated 2-arylbenzofurans. Specifically, two farnesylated 2-arylbenzofurans [morusalfurans B (2) and C (3)] showed strong inhibitory effects on PTP1B with IC50 values of 8.92 and 7.26 µM, respectively, which was significantly higher than that of the positive controls [sodium orthovanadate (IC50 = 15.10 µM) and ursolic acid (IC50 = 11.34 µM)]. Besides, two 2-arylbenzofurans [morusalfurans A (1) and F (6)], one flavonoid [morusalnol B (9)], and one geranylated stilbene [morusibene A (11)] exhibited PTP1B inhibition with IC50 values ranging from 11.02 to 26.56 µM. Kinetic studies revealed compounds 2, 3, 6, and 11 as mixed type PTP1B inhibitors, while 1 and 9 are known as noncompetitive. Molecular docking simulations demonstrated that these active compounds can bind with the respective catalytic or/and allosteric sites of PTP1B with negative binding energies and the results are in accordance with that of the kinetic studies. To the best of our knowledge, this is the first time, the PTP1B inhibitory activity of eleven compounds (1-11), as well as the mechanism of action underlying the effects on PTP1B enzyme of the active compounds, were investigated. In vitro and in silico results suggest that the farnesylated 2-arylbenzofurans from M. alba may potentially be utilized as an effective treatment therapy for type 2 diabetes mellitus and its associated complications.

• Authors: Manh Tuan Ha, Srijan Shrestha, Thu Huong Tran, Jeong Ah Kim, Mi Hee Woo, Jae Sue Choi, Byung Sun Min
• Journal: Archives of pharmacal research (Arch Pharm Res) Vol. 43 Issue 9 Pg. 961-975 (Sep 2020) ISSN: 1976-3786 [Electronic] Korea (South)
• PMID: 32978714 (Publication Type: Journal Article)

Chemical References

• Benzofurans
• Hypoglycemic Agents
• Insulin
• Plant Extracts
• PTPN1 protein, human
• Protein Tyrosine Phosphatase, Non-Receptor Type 1

Topics

• Allosteric Regulation (drug effects)
• Benzofurans (chemistry, isolation & purification, pharmacology)
• Catalytic Domain (drug effects)
• Diabetes Mellitus, Type 2 (drug therapy, metabolism)
• Enzyme Assays
• Humans
• Hypoglycemic Agents (chemistry, isolation & purification, pharmacology)
• Inhibitory Concentration 50
• Insulin (metabolism)
• Kinetics
• Molecular Docking Simulation
• Morus (chemistry)
• Plant Bark (chemistry)
• Plant Extracts (chemistry, isolation & purification, pharmacology)
• Plant Roots (chemistry)
• Prenylation
• Protein Tyrosine Phosphatase, Non-Receptor Type 1 (antagonists & inhibitors, metabolism)